Logotype for AbCellera Biologics Inc

AbCellera Biologics (ABCL) investor relations material

AbCellera Biologics Wells Fargo 20th Annual Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for AbCellera Biologics Inc
Wells Fargo 20th Annual Healthcare Conference 2025 summary5 Sep, 2025

Company evolution and strategic shift

  • Transitioned from a partnership and royalty-based model to developing an internal pipeline of therapeutic antibodies, leveraging advanced technology for difficult targets like GPCRs and ion channels.

  • Built integrated capabilities from target discovery to GMP manufacturing, with significant infrastructure and talent investments, supported by government funding.

  • Successfully brought first two proprietary antibodies, ABCL635 and ABCL575, into clinical trials in 2024, marking a major operational milestone.

  • Demonstrated strong execution by submitting two clinical trial authorizations (CTAs) in Q2 2024 and initiating patient dosing.

  • Maintains selective strategic partnerships for validation and portfolio management, while focusing on internal program advancement.

Pipeline highlights and clinical development

  • ABCL635 targets NK3R for non-hormonal treatment of hot flashes in postmenopausal women, addressing a $2 billion market with unmet need.

  • Phase one design includes biomarker-driven proof of concept, with efficacy and safety readouts expected by mid-2026.

  • ABCL575, an OX40 ligand antibody, aims for longer dosing intervals and is positioned as a potential second-line therapy in atopic dermatitis and other inflammatory conditions.

  • Additional proprietary program, ABCL688, is scheduled to enter the clinic in mid-2026, with a focus on complex membrane protein targets and similar market potential.

  • Plans to advance two new clinical candidates per year, with portfolio management decisions based on clinical data and market dynamics.

Capital allocation and business model

  • Holds over $500 million in cash and nearly $200 million in additional government funding, providing at least three years of operational runway.

  • Capital allocation strategy prioritizes advancing internal programs through phase one, with asset-by-asset decisions for later-stage development or partnerships.

  • Intends to partner or out-license certain assets, such as ABCL575, to optimize value and manage portfolio risk.

  • Continues to selectively sign new partnership and royalty deals, maintaining relationships with major pharma companies for both validation and future collaboration.

  • Royalty portfolio and partnered programs remain a source of potential upside, though not the primary growth driver.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next AbCellera Biologics earnings date

Logotype for AbCellera Biologics Inc
Q3 20256 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next AbCellera Biologics earnings date

Logotype for AbCellera Biologics Inc
Q3 20256 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

AbCellera Biologics, Inc. operates as a biotechnology company. The Company offers antibody discovery platform that accelerates the design of therapeutic antibodies and helps researchers discover new treatments for people with cancer or Alzheimer's disease. The company's platform discovers and characterizes fully human antibodies from natural immune responses in order to provide insights into how best to stimulate the human immune system.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage